Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay by Houldcroft, Charlotte J. et al.
ORIGINAL RESEARCH
published: 26 June 2020
doi: 10.3389/fcimb.2020.00275
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 June 2020 | Volume 10 | Article 275
Edited by:
Michael Nevels,




Hannover Medical School, Germany
Corey Smith,





This article was submitted to
Virus and Host,
a section of the journal
Frontiers in Cellular and Infection
Microbiology
Received: 11 March 2020
Accepted: 08 May 2020
Published: 26 June 2020
Citation:
Houldcroft CJ, Jackson SE, Lim EY,
Sedikides GX, Davies EL, Atkinson C,
McIntosh M, Remmerswaal EBM,
Okecha G, Bemelman FJ, Stanton RJ,
Reeves M and Wills MR (2020)
Assessing Anti-HCMV Cell Mediated
Immune Responses in Transplant
Recipients and Healthy Controls Using
a Novel Functional Assay.
Front. Cell. Infect. Microbiol. 10:275.
doi: 10.3389/fcimb.2020.00275
Assessing Anti-HCMV Cell Mediated
Immune Responses in Transplant
Recipients and Healthy Controls
Using a Novel Functional Assay
Charlotte J. Houldcroft 1, Sarah E. Jackson 1, Eleanor Y. Lim 1, George X. Sedikides 1,
Emma L. Davies 1, Claire Atkinson 2, Megan McIntosh 2, Ester B. M. Remmerswaal 3,4,
Georgina Okecha 1, Frederike J. Bemelman 3,4, Richard J. Stanton 5, Matthew Reeves 2 and
Mark R. Wills 1*
1Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge, United Kingdom, 2Division of
Infection and Immunity, Institute for Immunity and Transplantation, University College London, London, United Kingdom,
3Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of
Amsterdam, Amsterdam, Netherlands, 4 Renal Transplant Unit, Division of Internal Medicine, Academic Medical Centre,
Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 5Division of Infection and Immunity, School of
Medicine, Cardiff University, Cardiff, United Kingdom
HCMV infection, reinfection or reactivation occurs in 60% of untreated solid organ
transplant (SOT) recipients. Current clinical approaches to HCMV management include
pre-emptive and prophylactic antiviral treatment strategies. The introduction of immune
monitoring to better stratify patients at risk of viraemia and HCMVmediated disease could
improve clinical management. Current approaches quantify T cell IFNγ responses specific
for predominantly IE and pp65 proteins ex vivo, as a proxy for functional control of HCMV
in vivo. However, these approaches have only a limited predictive ability. We measured
the IFNγ T cell responses to an expanded panel of overlapping peptide pools specific for
immunodominant HCMV proteins IE1/2, pp65, pp71, gB, UL144, and US3 in a cohort
of D+R– kidney transplant recipients in a longitudinal analysis. Even with this increased
antigen diversity, the results show that while all patients had detectable T cell responses,
this did not correlate with control of HCMV replication in some. We wished to develop
an assay that could directly measure anti-HCMV cell-mediated immunity. We evaluated
three approaches, stimulation of PBMCwith (i) whole HCMV lysate or (ii) a defined panel of
immunodominant HCMV peptides, or (iii) fully autologous infected cells co-cultured with
PBMCor isolated CD8+ T cells or NK cells. Stimulation with HCMV lysate often generated
non-specific antiviral responses while stimulation with immunodominant HCMV peptide
pools produced responses which were not necessarily antiviral despite strong IFNγ
production. We demonstrated that IFNγ was only a minor component of secreted
antiviral activity. Finally, we used an antiviral assay system to measure the effect of
whole PBMC, and isolated CD8+ T cells and NK cells to control HCMV in infected
autologous dermal fibroblasts. The results show that both PBMC and especially CD8+ T
cells from HCMV seropositive donors have highly specific antiviral activity against HCMV.
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In addition, we were able to show that NK cells were also antiviral, but the level of this
control was highly variable between donors and not dependant on HCMV seropositivity.
Using this approach, we show that non-viraemic D+R+ SOT recipients had significant
and specific antiviral activity against HCMV.
Keywords: herpesvirus, host-pathogen interactions, secreted immunity, T cells, transplantation, cell-mediated
immunity, antiviral, cytomegalovirus
INTRODUCTION
Human cytomegalovirus (HCMV) remains a significant cause
of mortality and morbidity in adult and pediatric solid organ
(Razonable, 2005) and hematopoietic stem cell (Hiwarkar et al.,
2013) transplant recipients. Viraemia in solid organ transplant
(SOT) recipients can result from a primary infection, reinfection,
superinfection with multiple strains (Görzer et al., 2010; Cudini
et al., 2019), or from reactivation of the host’s own HCMV
strain(s) (Atabani et al., 2012). HCMV viraemia and disease
in SOT recipients is associated with a number of risk factors,
including organ type (with larger transfers of lymphoid tissue
conveying higher risk, due to the larger latent virus load
present) (Razonable and Humar, 2013), the degree of immune
suppression (required to prevent organ rejection) the SOT
recipient is receiving, as well as other co-infections and co-
morbidities and relative HCMV serostatus (Razonable, 2005;
Atabani et al., 2012).
Relative HCMV serostatus can be used to divide solid organ
donors and recipients into four groups with distinct HCMV
viraemia and disease risk profiles. Donor seronegative, recipient
seronegative (D–R–) solid organ transplants have the lowest
likelihood of HCMV infection or disease. Donor seronegative,
recipient seropositive (D–R+) transplants have a low risk of
viraemia, as the recipient has pre-existing cellular immunity
to HCMV and no exogenous HCMV strains are introduced
by the donor organ; HCMV viraemia comes from reactivation
of the recipient’s own virus(es). Donor seropositive, recipient
seropositive transplants (D+R+) have an intermediate risk of
viraemia, because while the recipient has pre-existing immunity,
HCMV re-infection or superinfection by donor strains may
occur, as well as reactivation of the recipient’s own HCMV.
The highest risk of HCMV viraemia and disease is seen in
donor seropositive, recipient seronegative (D+R–) transplants.
In this situation, the donor organ can transmit HCMV to
the immunologically HCMV-naïve recipient, causing primary
infection with one or more HCMV strains (Atabani et al., 2012).
Antiviral prophylaxis and pre-emptive treatment are
important tools for the prevention and management of HCMV
disease in immune suppressed populations (Lumley et al.,
2019). Using a prophylactic treatment strategy, all patients
considered at risk of HCMV viraemia and disease receive
antiviral treatment for a defined period of time immediately
post-transplant. In contrast, pre-emptive treatment monitors
asymptomatic patients for evidence of HCMV replication
[DNAemia measured by quantitative nucleic acid testing
(QNAT)] and treats with antivirals once a threshold is reached
(Razonable and Humar, 2019). In clinical practice, this means
that pre-emptive treatment requires frequent (e.g., twice-weekly)
monitoring of HCMV DNA in blood, and commencing antiviral
treatment at a defined DNAemia threshold, for example 2,520
IU/ml (Griffiths et al., 2016). Recent data suggest that the
prophylactic strategy requires less intensive patient monitoring
in SOT, and is associated with lower viraemia and a lower risk
of HCMV reactivation/reinfection compared to pre-emptive
treatment (Griffiths, 2019). However prophylactic treatment also
leads to an increased risk of late-onset disease due to poorer cell-
mediated immunity in D+R– transplants (Limaye et al., 2019);
and poorer patient outcomes, including reduced kidney function
and increased risk of graft rejection (Blazquez-Navarro et al.,
2019). There is conflicting evidence as to whether prophylaxis
significantly increases the risk of drug resistance (Hakki and
Chou, 2011; López-Aladid et al., 2017). However, it is notable
that HCMV viraemia and disease only seems to occur in a subset
of these “at-risk” individuals.
The occurrence of HCMV viraemia and disease in patient
groups with T cell immune deficiencies (untreated HIV/AIDS,
inborn errors of immunity) or suppression (SOT recipients)
highlights the importance of cell-mediated immunity (CMI)
in the control of HCMV (Fiala et al., 1986; Bowen et al.,
1997; Bunde et al., 2005; Gerna et al., 2006; McLaughlin et al.,
2017). The practice of clinical monitoring for development
of HCMV-specific immunity using HCMV-specific interferon
gamma (IFNγ) production has been studied in both solid organ
and hematopoietic stem cell transplant recipients and has gained
traction in recent years. In solid organ transplant recipients,
the utility of such an approach is in assessing the risk of late-
onset HCMV disease after cessation of prophylaxis in high-
risk (D+R–) transplant recipients, predicting seropositive (R+)
patients who may spontaneously clear HCMV infection (Kumar
et al., 2018), and predicting risk of relapse of HCMV viraemia
or disease (Haidar et al., 2020). In contrast, the predictive
power of CMI assays was much lower in high-risk seronegative
(R–) SOT recipients (Kumar et al., 2018; Haidar et al., 2020),
where an effective assay might yield the greatest benefit. In
the hematopoietic stem cell transplant population, immune
monitoring is used with pre-emptive treatment strategies and
can be used to predict early or recurrent reactivation, to shorten
duration of anti-HCMV therapy, and to predict individuals
likely to clear HCMV infection spontaneously (Yong et al.,
2018). The main advantage offered with immune monitoring
is to allow clinicians to tailor the use of antiviral therapies,
thereby reducing the attendant therapeutic complications,
such as myelosuppression with ganciclovir/valganciclovir, and
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electrolyte imbalances with foscarnet. Better immunemonitoring
would also allow for the preparation of e.g., HCMV-specific
therapeutic T cells in patients thought highly likely to fail
antiviral therapy (Neuenhahn et al., 2017). This group would
include patients with pre-existing antiviral resistance mutations
or patients infected withmore than oneHCMV strain (Coaquette
et al., 2004; Lisboa et al., 2011). These factors may overlap with
and be exacerbated by poor cell-mediated antiviral immunity.
However, the limitations of immune monitoring, such as high
costs, slow turnaround times, and lack of standardization remain
to be addressed (Haidar et al., 2020).
There are a number of assays currently used to provide an
ex vivo measure of HCMV-specific cellular immunity. Immune
monitoring assays can be broadly placed in to four groups.
EliSpot-based assays, such as T-Spot (Kumar et al., 2018) and
T-Track (Banas et al., 2017), use peptides from pp65 and IE1/2
and enumerate CD4+ and CD8+ T cell responses. However,
individuals responding to epitopes from other HCMV proteins
would not be covered by these assays, although the assay
is HLA-agnostic. While EliSpot-based assays can be adapted
to analyse a wider range of antigens (whether with HCMV
lysate or peptide pools), this approach is more often used for
research than clinical assays (e.g., Mohty et al., 2004; Goodell
et al., 2007; Jackson et al., 2017b). There are also ELISA-based
assays, such as QuantiFERON-CMV (Qiagen) (Walker et al.,
2007). QuantiFERON-CMV measures CD8+ T cell responses
to 22 defined epitopes from IE1 and 2, pp28, pp50, pp65,
and gB with restricted HLA coverage, and may be confounded
by lymphopenia (Giulieri and Manuel, 2011). MHC class I
HCMV tetramer/multimer peptide complex staining (Yong et al.,
2018) allows the detection and quantification of HCMV-specific
cytotoxic CD8+ T cells, covering known epitopes in pp50,
pp65, and IE1 (Borchers et al., 2011). These HCMV-specific
CTLs are associated with protection from viraemia in some
patient populations, although not currently considered predictive
(Kotton et al., 2018). Flow cytometry-based intracellular cytokine
staining is also used for research applications, but is not as
widely used for diagnostic purposes (Fernández-Ruiz et al., 2018)
because of the requirement for flow cytometry equipment and
expertise (Rogers et al., 2020), despite its potential to predict
both viraemia and disease (Kotton et al., 2018). Most non-flow
cytometry-based approaches are restricted to peptides recognized
specifically by HLA types more common in populations of
European descent. More generally, these assays aremeasuring the
ability of a T cell to respond to an antigen and using that as a
correlate of inferred antiviral activity.
The majority of these HCMV-immune monitoring assays,
and particularly the EliSpot/FluoroSpot and ELISA-based assays,
focus on production of a single cytokine in response to
HCMV—IFNγ. There are problems with both the negative
and positive predictive value of these assays (Chanouzas et al.,
2018; Deborska-Materkowska et al., 2018; Jarque et al., 2018;
Fernández-Ruiz et al., 2020); while other prospective studies
have found positive IFNγ EliSpot responses to be predictive
of protection against HCMV viraemia or disease necessitating
a change in treatment strategy (Kumar et al., 2019). IFNγ
responses to HCMV as measured by ELISA and EliSpot are
clearly measuring part—but not all—of HCMV CMI, because
viraemia can occur in the presence of IFNγ responses to HCMV;
and viraemia does not necessarily occur in the absence of IFNγ
responses to HCMV. As such it is likely that other secreted and
cell-mediated factors are involved, including CMI responses to
epitopes not included in most commercial assays; other cytokines
with antiviral activity; the responses of other arms of the immune
system beyond CD8+ T cells [e.g., CD4+ T cells (Watkins
et al., 2012); NK cells (Venema et al., 1994); monocyte-derived
macrophages (Becker et al., 2018); γδ T cells (Knight et al., 2010;
Kaminski et al., 2016); antibodies (Baraniak et al., 2018)]; and
host and viral genetic variation (Sezgin et al., 2019; Suárez et al.,
2019).
In this study we have examined by FluoroSpot the IFNγ
response to overlapping peptides from a much broader range of
immunodominant HCMV proteins in D+R– kidney transplant
recipients experiencing primary HCMV infection, correlated
with patient DNAemia over a time course post-transplantation.
These results show that detection of HCMV-specific T cells
at frequencies similar to normal healthy controls was not
predictive of the ability to control episodes of viraemia. We
have also studied the antiviral activity of supernatants derived
from PBMC stimulated with HCMV-infected cell lysate as well
as immunodominant peptide pools in a virus dissemination
assay system. Using this system, we demonstrated that lysate and
peptide stimulation of PBMC are imperfect ways to measure
HCMV secreted antiviral immunity, as many donors reacted
non-specifically to lysate stimulation or did not produce antiviral
responses to peptide stimulation. Finally, we utilized a fully
autologous virus dissemination assay co-cultured with whole
PBMC, CD8+ T cells, or NK cells to determine the antiviral
capacity of these immune effectors against HCMV-infected
fibroblasts. In healthy donors both whole PBMC and isolated
CD8+ T cells were highly effective in the control of HCMV
replication. The results of the NK cell co-cultures show that
while some donors were able to control HCMV replication,
other donors had much poorer antiviral activity. We then
demonstrate that PBMC and CD8+ T cells derived from D+R+
kidney transplant recipients who control their viraemia post-
transplant, could control HCMV dissemination similarly to an
immunocompetent, healthy HCMV seropositive individual. Our
data lead us to conclude that autologous cell-mediated assays
are the most powerful way to characterize the functionality
of the antiviral immune response to HCMV. Importantly, this
approach will allow us to stratify patients based on the ability
of their CMI to control HCMV ex vivo and, furthermore, could
have important implications for our understanding of the key
elements of the immune response which are important for the
control of HCMV.
MATERIALS AND METHODS
Recruitment: Kidney Transplant Recipients
Seven seropositive donor to seronegative recipient (D+R–)
kidney transplant patients were recruited by Academisch
Medisch Centrum (AMC), Amsterdam, who experienced
primary HCMV infection post-transplantation. Transplants took
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place between 2003 and 2009. Ethical permission was granted
by the Medical Ethics Committee of the AMC, Amsterdam and
all patients gave informed written consent in accordance with
the Declaration of Helsinki. Donor and recipient serostatus
were defined using a microparticle enzyme immunoassay
as previously described (Remmerswaal et al., 2012). PBMC
were collected at multiple time points after transplantation,
with subsequent samples collected at varying time points up
to a maximum of 158 weeks post-transplantation, isolated
by density centrifugation and cryopreserved (Remmerswaal
et al., 2012). Virus load monitoring was performed by
quantitative PCR (qPCR) as previously described (Boom
et al., 1999). PBMC were a kind gift from Professors I. J.
M. ten Berge and R. A. W. van Lier (Amsterdam Renal
Transplant Unit).
Four seropositive donor to seropositive recipient (D+R+)
kidney transplant patients were recruited by the Royal Free
Hospital, London. Ethical permission for “UCL17-0008 Analysis
of Cytomegalovirus Pathogenesis in Solid Organ Transplant
Patients Study” was granted by the London—Queen Square
Research Ethics Committee (REC reference 17/LO/0916).
Informedwritten consent was obtained from all patients included
in this study prior to providing pseudo-anonymised research
samples (blood, urine, saliva, skin, and bile). No patients in the
UCL cohort received antiviral therapy as they did not develop
detectable DNAemia, following previously published treatment
guidelines (Griffiths et al., 2016). Virus load (DNAemia)
monitoring was performed by qPCR as previously described
(Mattes et al., 2005; Atabani et al., 2012).
For all donors used in this study, PBMC derived from blood
samples were collected and stored in a cell bank for subsequent
analysis. The study was designed in this way for two reasons,
firstly because of the time required to grow out a human dermal
fibroblast line (weeks) which are required for the autologous viral
dissemination assays. Secondly, the assays developed in these
studies are to be used in a longitudinal analysis of D+R– patients
post-transplantation to understand which immune responses
confer protection from viraemia. Blood samples collected for
PBMC isolation and determination of viraemia will be taken
at regular time points post-transplantation so that PBMC from
time points with and without viraemia could be assayed at
multiple time points in parallel. T cell responses from normal
healthy volunteers were thus treated in same way. Our freezing
and thawing protocols are defined and consistent, and where
appropriate an anti CD3/CD28 positive control is included, such
that donors that failure to respond to polyclonal stimulation are
excluded from analysis.
Patients are summarized in Table 1 and Supplementary
Table 1 (D+R–) and Supplementary Table 2 (D+R+).
Recruitment: Healthy Volunteers
HCMV seronegative and seropositive individuals were recruited
in younger (<40 years of age) and older (65> years of age)
groups, donating either PBMC (ARIA study; Jackson et al.,
2017b) or PBMC and autologous primary dermal fibroblasts
(AQUARIA study).
TABLE 1 | Participant characteristics.




































HCMV seropositive and seronegative donors were recruited
in three stages. Ten donors were recruited locally with
ethical approval from the Cambridge Central Research Ethics
Committee (97/092). Eleven donors were previously recruited
by the NIHR BioResource Centre Cambridge through the
ARIA study (Jackson et al., 2017b), with ethical approval from
the Cambridge Human Biology Research Ethics Committee
(HBREC.2014.07). Sixteen donors were recruited by the NIHR
BioResource Centre Cambridge through the AQUARIA study,
with ethical approval from the North of Scotland Research
Ethics Committee 1 (NS/17/0110). Donors were excluded if they
were receiving immunosuppressive therapy, e.g., cyclosporins
or methotrexate.
In each case, informed written consent was obtained from all
volunteers in accordance with the Declaration of Helsinki.
Healthy volunteers are summarized in Table 1.
Isolation of Human Dermal Fibroblasts
Primary human dermal fibroblasts (HDFs) were obtained from
individual donors in the AQUARIA study and the D+R+ kidney
transplant cohort. A 2-mm punch biopsy was obtained from
each donor. HDFs were grown out from this biopsy following a
previously published protocol (Poole et al., 2014), modified to use
DMEM (Poole et al., 2020).
Peripheral Blood Mononuclear Cell (PBMC)
Isolation
Peripheral blood mononuclear cells were isolated from
heparinized blood samples using Histopaque R©-1077 (Sigma-
Aldrich, Poole, UK) or Lymphoprep (Axis-shield, Oslo,
Norway) density gradient centrifugation. HCMV serostatus was
assessed using an IgG enzyme-linked immunosorbent assay
(Trinity Biotech Plc, Co., Wicklow, Ireland). Patient, ARIA and
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local donor PBMC were frozen in liquid nitrogen in a 10%
dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and 90% SeraPlus
fetal bovine serum (PAN Biotech, Wimborne, UK) solution;
AQUARIA PBMC were frozen in a serum-free freezing media
composed of 60% IMDM (Iscove’s Modified Dulbecco’s Medium,
Sigma), 10% DMSO, and 30% Panexin serum replacement (PAN
Biotech). Frozen PBMC were rapidly thawed, and the freezing
medium was diluted into 10ml of fresh X-Vivo 15 (Lonza,
Slough, UK). PBMC were incubated at 37◦C with 10 U/ml
DNase (Benzonase, Merck-Millipore via Sigma-Aldrich) for
1 h, followed by resuspension in fresh media and an overnight
incubation at 37◦C.
Specific Cell Subtype Isolation
PBMC were enriched for CD8+ T cells or NK cells by
magnetically activated cell sorting (MACS) using CD8+ T
cell (130-096-495) or NK cell (130-092-657) isolation kits
(Miltenyi Biotech,Woking, UK), according to the manufacturer’s
instructions. Cells were separated by use of an autoMACS Pro
separator (Miltenyi Biotech). The efficiency of depletion was
determined by staining cells as described in the phenotyping
method below. Depletions performed in this manner resulted in
0–0.3% residual CD4+ T cell content of CD8+ cell fractions, and




The virus used in this study was based on a BAC cloned version
of HCMV strain Merlin (Wilkinson et al., 2015). This contains
the complete wildtype HCMV genome, with the exception of
point mutations in RL13 and UL128, which enhance growth
in fibroblasts (Stanton et al., 2010). Two genes were tagged
with fluorescent markers. UL36 was linked to mCherry via a
P2A linker. This arrangement results in expression of mCherry
at immediate early times (Nightingale et al., 2018). UL32 was
linked directly to GFP via a six amino-acid linker, and results
in GFP expression at late times (Weekes et al., 2014). Both
constructs were generated by recombineering as previously
described (Stanton et al., 2008). In both cases, a recombineering
cassette expressing kanR, lacZa, and rpsL was first inserted at the
site of modification, following PCR amplification using primers
in Supplementary Table 3. For GFP fusions to UL32, the primers
listed in Supplementary Table 3 were used to amplify GFP and
switch the recombineering cassette for the linker-GFP sequence.
For insertion of P2A-mCherry after UL36, the insertion was gene
synthesized by Geneart, digested to release it from its original
vector, gel purified, and used to replace the recombineering
cassette. All constructs were sequenced by Sanger sequencing
across the site of modification, including any inserted sequence.
Virus Propagation
HCMV strainMerlin mCherry-P2A-UL36 GFP-UL32 was grown
in human foreskin fibroblasts (HFF), following the protocol in
Wills et al. (2005). The infectious titer and PFU were calculated
using the method in Jackson et al. (2017a).
HCMV-Infected Cell Lysate and Control
Fibroblast Lysate
One T175 flask of MRC-5 fibroblasts was maintained in
DMEM [Sigma, Poole, UK] with 10% FCS [PAA, Linz,
Austria] and pen-strep [105 IU penicillin/L, and 100mg
streptomycin/L (Invitrogen Life Technologies)]. When cells were
80% confluent, they were infected with dual-color Merlin and
the virus was propagated for 14 days at 37◦C in a 5% CO2
humified atmosphere. When 80% of cells were mCherry+ or
mCherry+GFP+ by fluorescent microscopy, the infected cells
were harvested using trypsin. A second T175 flask of MRC-5
fibroblasts was used as control fibroblast lysate and was harvested
when cells were 95% confluent. Cells were resuspended in 10ml
DMEM with 10% FBS and placed in a 50ml Falcon. Cells were
subjected to three freeze-thaw cycles to lyse the cells, alternating
between a dry-ice/ethanol bath and 37◦C water bath. The lysed
cell suspension was then centrifuged for 7min at 700RPM and
the supernatant (the lysate) drawn off and frozen in 1ml aliquots
were stored at−80◦C until further use. Lysates were heat-treated
at 56◦C for 30min before subsequent application (Nokta et al.,
1996; Hodinka, 2007).
HCMV ORF Peptide Pools
Seven HCMV proteins were selected based on previously
demonstrated immunogenicity (Jackson et al., 2014, 2017a)
and peptide libraries comprising consecutive 15mer peptides
overlapping by 10 amino acid were synthesized by ProImmune
PEPScreen (Oxford, UK) and JPT Peptide Technologies
GmbH (Berlin, Germany). Individual lyophilized peptides were
reconstituted and used as previously described (Jackson et al.,
2014) in peptide pools at a concentration of 5 µg/ml/peptide.
The peptide pools covered the following ORFs: gB (UL55); pp65
(UL83) and UL144; IE1 (UL123) and IE2 (UL122); pp71 (UL82)
and US3.
Cytokine Quantification by Enzyme-Linked
Immunosorbent Assay (ELISA)
The Human IFNγ ELISA MAX Standard Set (Biolegend,
London, UK) was used to quantify IFNγ concentrations
in supernatants. ELISAs were performed according to the
manufacturer’s recommended protocol.
Detection of Cytokine Production by
FluoroSpot
To maximize available cell numbers, 1 × 105 total PBMC were
suspended in X-VIVO 15 (Lonza, Slough, UK) supplemented
with 5% Human AB serum (Sigma Aldrich). PBMC were
incubated in pre-coated human IFNγ and IL-10, or IFNγ, IL-
10, and TNFα FluoroSpot plates (Mabtech AB, Nacka Strand,
Sweden) in triplicate with ORF peptide pools (final peptide
concentration 2µg/ml following dilution with X-Vivo-15) and
an unstimulated and positive control mix [containing anti-CD3
and anti-CD28 (Mabtech AB) or colloidal anti-CD3 and anti-
CD28 (Human T cell TransAct, Miltenyi Biotech), at 37◦C
for 48 h]. Cells and media were decanted from the plate and
the assay developed following the manufacturer’s protocol.
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Developed plates were read using an AID iSpot reader (Oxford
Biosystems, Oxford, UK) and counted using AID EliSpot v7
software (AutoimmunDiagnostika GmbH, Strasberg, Germany).
Donor results were discounted from further analysis if there
was >1,000 spot forming units (sfu) per well. The sfu response
in the positive control (mitogen stimulation) wells had to be at
least 100 sfu/well greater than the background sfu/well, otherwise
the sample failed quality control and was excluded. The mean sfu
of triplicate wells were converted to sfu per 106 cells, the mean
background response (sfu/106 cells) was deducted from the mean
responding wells. The cut off to define a positive IFNγ response
was responses >100 sfu/106 cells, negative responses were below
this. The cut off was determined by comparing the distribution of
the responses from HCMV seropositive and seronegative donors
to HCMV protein stimulation and the positive control in our
previous ARIA study results (Jackson et al., 2017b).
Generation of Supernatants Following
Lysate Stimulation
3 × 105 total PBMC were suspended in X-VIVO 15 (Lonza,
Slough, UK) in a 5ml polypropylene tube and stimulated with
heat inactivated HCMV [Merlin]-infected fibroblast lysate or
uninfected fibroblast lysate, and positive control mixes (anti-
CD3 and anti-CD28, as above). They were incubated at 37◦C,
in a 5% CO2 atmosphere for 48 h. Tubes were spun for
10min at 2000RPM to pellet the PBMC. Two milliliters media
(the supernatant) was then removed from each tube without
dislodging the cell pellet and frozen at−80◦C.
Generation of Supernatants Following
Peptide Stimulation
3 × 105 total PBMC were suspended in X-VIVO 15 (Lonza,
Slough, UK) in a 5ml polypropylene tube and stimulated with
ORF peptide pools and unstimulated (X-VIVO 15) and positive
control mixes. They were incubated at 37◦C in a 5% CO2
atmosphere for 48 h and supernatants harvested as above.
Virus Dissemination Assay:
Non-autologous
Human fetal foreskin fibroblasts (HFFFs) were maintained in
DMEM [Sigma, Poole, UK] with 10% FCS [PAA, Linz, Austria]
and pen-strep [105 IU penicillin/L, and 100mg streptomycin/L
(Invitrogen Life Technologies)]. HFFFs were seeded at 2.5 ×
104 cells/well in a 96-well plate. After 48 h, cells were confluent
and were infected at a low MOI (0.01) with mCherry-GFP-
Merlin. After a further 24 h, 75 µl of lysate or peptide-stimulated
supernatant was added to each well. After 9–11 days, cells were
harvested with trypsin and fixed in a 2% PFA solution for flow
cytometry analysis of viral dissemination.
Viral spread in each well was determined as a percentage
of control wells lacking supernatants using the following
equation ([Experimental % of infected cells – background %
of HFFF-only control]/[% of infected HFFF control without
effector cells/supernatants – background % of HFFF-only
control])× 100.
Virus Dissemination Assay: Autologous
Human primary dermal fibroblasts (HDFs) were maintained in
DMEM [Sigma, Poole, UK] with 20% FCS [PAA, Linz, Austria]
and pen-strep [105 IU penicillin/L, and 100mg streptomycin/L
(Invitrogen Life Technologies)].Where paired HDFs and effector
cells (PBMC; CD8+; NK) were available from healthy volunteers,
1 × 104 HDFs were seeded in each well of a half-area 96-well
plate (Greiner Bio-One, Stroudwater, UK). After 48 h, cells were
confluent and were infected at a low MOI (0.01) with mCherry-
GFP-Merlin HCMV. After a further 24 h, cells were seeded at a
range of effector to target ratios in X-Vivo 15 (Lonza, Slough,
UK). After 10–14 days, PBMC or effector cells were washed off
and HDFs were harvested with trypsin and fixed in a 2% PFA
solution for flow cytometry analysis of viral spread.
Viral spread in each well was determined as
described previously.
Phenotyping
105 total PBMC was stained in separate tubes with two
phenotyping cocktails containing 2 µl of each antibody:
T cell antibody mix: anti-CD3—fluorescein isothiocyanate
(FITC), clone UCHT1; anti-CD4—phycoerythrin (PE), clone
RPA-T4; anti-CD8a-peridinin-chlorophyll protein—cyanine 5.5
(PerCP Cy5.5), clone RPA-8a (all BioLegend, London, UK),
LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo
Fisher Scientific).
NK cell antibody mix: anti-CD3-FITC; anti-CD8-PerCP
Cy5.5 (both as before); anti-CD56-PE, clone B159 (BD
Pharmingen); LIVE/DEAD Fixable Far Red Dead Cell Stain Kit.
Flow Cytometry
Flow cytometry analysis of dual-color virus dissemination was
performed on the BD Fortessa2 or Thermo Fisher Attune NxT
flow cytometers. PBMC phenotyping was performed on the BD
Accuri C6 flow cytometer. Data were analyzed with FlowJo v10
(Becton Dickinson, Wokingham, UK).
Statistical and Graphical Analysis
Data presentation and statistical analyses was performed using
GraphPad Prism v8. Statistical significance for one-tailed T-
tests was determined with an alpha = 0.05, without assuming a
consistent standard deviation between populations.
RESULTS
Longitudinal Detection of HCMV-Specific
IFNγ CD3+ T Cell Responses in D+R–
Kidney Transplant Recipients Did Not
Predict Resolution of Viraemia
IFNγ T cell responses to HCMV in vitro have previously
been used as a surrogate measure of the level of cell-
mediated immunity to HCMV in vivo. To begin testing
this assumption, we characterized the development of IFNγ
T cell responses following primary HCMV infection. To
do this, CD3+ T cell IFNγ responses to HCMV peptide
pools were measured by Fluorospot on a cohort of D+R–
kidney transplant patients, all of whom experienced
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primary HCMV infection following transplantation. In
the seven patients studied, all developed robust IFNγ
responses to a range of HCMV peptide pools, covering
lytic proteins gB, IE1, IE2, US3, pp65, UL144, and
pp71, responses enumerated by FluoroSpot (Figure 1 and
Supplementary Figure 1).
However, these longitudinal analyses revealed examples
of two broadly distinct patterns of response in this cohort
(Figure 1). In some patients (3/7 e.g., Pt365) (Figure 1A), we
observed the generation of a HCMV-specific IFNy CD3+ T
cell response which was sustained over time and correlated
with the resolution of initial viraemia. Subsequent episodes
of viraemia where not observed after this response became
detectable. In other patients, viraemia recurred once (3/7
e.g., Pt574; Supplementary Figure 1) or several times (1/7
e.g., Pt352; Figure 1B), despite detectable HCMV-specific IFNy
CD3+ T cell responses of similar magnitude being present
at the times of recrudescence. As such, the results show
that in this group of patients, CD3+ T cell IFNγ responses
as measured by FluoroSpot were not necessarily predictive
of the resolution of CMV viraemia, even when a broad
selection of highly immunogenic HCMV peptide pools was
used. Importantly, a comparison of the magnitude of these
responses with a previously studied cohort of healthy seropositive
donors in the same age range as each transplant recipient
(Jackson et al., 2017b) revealed the CD3+ T cell IFNγ
FluoroSpot responses of these seven D+R– patients were of
a similar magnitude and breadth arguing that these patients
can generate substantial T cell responses when measured by
IFNy Fluorospot.
Determination of Antiviral Efficacy of
HCMV Antigen Stimulated PBMC and Its
Correlation to IFNγ Detection-Based
Assays
We speculated that one explanation for the inconsistent
predictive power of simply measuring CD3+ HCMV-specific T
cell IFNγ responses as a correlate with in vivo HCMV control
could be that other cytokines and secreted factors may also
play an important role in antiviral T cell immunity to HCMV
(Nachtwey and Spencer, 2008; Mason et al., 2013; Siewiera et al.,
2013).
In order to address this the capacity of the CD3+ T cells
to control viral replication we adapted a viral dissemination
assay (VDA) previously used by our group to quantify the
spread of virus through indicator fibroblasts co-cultured
with NK cells or CD8+ T cells (Jackson et al., 2014; Chen
et al., 2016). Using a dual mCherry-GFP expressing strain of
HCMV (Merlin), the progression of infection can be assayed.
Infected cells express mCherry from immediate-early times
post-infection (linked to UL36-P2A-mCherry) and are both
mCherry and GFP+ (fused to UL32 [pp150 – tegument
protein]) at late times post-infection. Following a low MOI
infection, the virus spreads through fibroblasts over time.
The infected mCherry+ and mCherry+ GFP+ cells can be
visualized using fluorescent microscopy and enumerated
by two color flow cytometry (Figure 2A), quantifying
viral dissemination kinetics over a series of time points
(Figure 2B).
Prior to the specific analysis of the supernatants derived
from T cells stimulated by HCMV antigens, we first determined
whether supernatant from PBMC incubated with anti-CD3 and
anti-CD28 antibodies to polyclonally activate the T cells (Trickett
and Kwan, 2003) was antiviral compared to unstimulated PBMC
control from the same donor. To test for any antiviral activity,
supernatants were added to cultures of HFF fibroblasts that
had been previously infected with HCMV overnight at low
MOI (0.01). The data show that supernatants taken from
antibody-stimulated T cells reduced the percentage of both
mCherry+ fibroblasts and mCherry+ GFP+ fibroblasts in a
titratable manner (Figure 2C). Although some antiviral activity
was evident using supernatants from unstimulated PBMC
(particularly when fibroblasts were analyzed for GFP expression),
this activity was considerably lower than following polyclonal
T cell activation. An analysis of supernatants from activated T
cells from multiple donors (n = 10) revealed that the level of
antiviral activity induced varied considerably between donors
(Figure 2D).
It was noted that following overnight infection, and addition
of PBMC derived supernatants, that the initial infected cells
(identified as mCherry+) proceeded to late gene expression
(i.e., became GFP+) after a further 48 h incubation, even
in the presence of a supernatant identified as antiviral. We
hypothesized, therefore, that the antiviral effects observed were
due to inhibition of the secondary infections that occur in our
VDA rather than an inhibition of the first round of infected cells.
These subsequent rounds of infection (spread) can be measured
if immediate early gene expression occurs (mCherry+ cells)
and/or subsequent progression to late viral gene expression by
GFP expression is impacted. As such, two scenarios are possible:
uninfected cells incubated with these supernatants might become
refractory to HCMV infection or induced into an antiviral state
which disrupts normal temporal viral gene expression between
immediate early and late viral gene expression. We therefore
subsequently define a reduction in the relative percentage of
cells which are mCherry+GFP– as a reduction in virus spread
in the culture. If a reduction in the relative percentage of
cells which are mCherry+ and GFP+ is observed (and thus
a reduction in progression to late gene expression), we can
use this as a proxy for a reduction in the number of new
infections in the VDA capable of producing new infectious
virus particles.
Having established that we could generate and define
antiviral supernatants by polyclonal T cell stimulation of
PBMC, we then wished to study the HCMV-specific secreted
antiviral immune response of PBMC from healthy seropositive
volunteers. Healthy donor PBMC was stimulated with heat-
treated HCMV-infected fibroblast lysate (“lysate”), and harvested
supernatants tested for antiviral activity in our VDA. The
results show that the outcome of PBMC stimulation is variable.
Some seropositive donors (e.g., ARIA219) generated HCMV-
specific antiviral supernatants, as they reduced the number
of mCherry+GFP+ fibroblasts. In contrast, supernatants from
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FIGURE 1 | Analysis of longitudinal HCMV virus load and HCMV specific CD3+ T cell IFNγ responses of D+R– Kidney transplant patients. Two example D+R– kidney
transplant patients with primary HCMV infection, T cell responses (spot forming units per 106 CD3+ T cells) were measured by IFNγ FluoroSpot (green triangles
connected by a solid line) to HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71 and US3, and gB, as well as a polyclonal T cell stimulation as a
positive control (“POS”). Virus load (copies/ml blood) was measured by QNAT of HCMV DNA (pink hexagons connected by a dashed line). Cyan lines show the mean
magnitude of response (±standard error) of CD3+ T cell IFNγ responses seen in healthy seropositive individuals in the same age decade as the transplant recipient for
each peptide pool (Jackson et al., 2017b). (A) Patient 365 is an example of a D+R– patient with resolution of DNAemia following the emergence of detectable CD3+
IFNγ responses to four HCMV lytic peptide pools. (B) Patient 352, in contrast, had DNAemia which recurred several times, despite also developing detectable HCMV
specific CD3+ T cell IFNγ responses which are comparable in frequency to those seen age-matched in healthy seropositives.
PBMC taken from donor ARIA177 show comparable inhibition
of virus by both the uninfected control fibroblast lysate and the
HCMV-infected lysate stimulation. Other donors had a weak
antiviral response to HCMV, such as ARIA211 (Figure 3A).
ARIA177 supported the hypothesis that non-self-antigens from
the fibroblasts used to produce the lysate may have stimulated
a non-specific antiviral response from some donors—which
would be consistent with our observations with supernatants
from polyclonally stimulated T cells. We therefore adapted
this assay to use the gB, IE1, IE2, US3, pp65, UL144, and
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FIGURE 2 | Quantification of HCMV dissemination and antiviral effect of polyclonally stimulated T cells. (A) Viral dissemination assay using a dual-fluorescently tagged
HCMV strain (Merlin mCherry-P2A-UL36 [vICA], GFP-UL32 [pp150]). Following a low MOI (0.01) infection of indicator fibroblasts, infected cells become mCherry+ as
the virus enters the immediate-early life cycle, and later become mCherry+ GFP+ as the virus enters the late life cycle. The percentage of cells infected can be
visualized by fluorescent microscopy and quantified by two color flow cytometry. (B) Kinetics of virus dissemination in HFFF cells. Virus dissemination has been
quantified by flow cytometry at various time points post-infection based on mCherry+ GFP– cells and on mCherry+ GFP+ cells. (C) Analysis of antiviral activity of
supernatant from anti-CD3/CD28 stimulated T cells in PBMC (supernatant donor ARIA060). Fibroblasts were infected at 0.01 MOI and co-cultured with dilutions of
supernatant, following 10 days of incubation fibroblasts were harvested and analyzed for mCherry and GFP expression by flow cytometry. (D) Analysis of antiviral
activity of supernatant from anti-CD3/CD28 stimulated T cells in PBMC from 10 independent donors, diluted 1:4. Fibroblasts were infected at 0.01 MOI and
co-cultured with dilutions of supernatant, following 9–11 days of incubation fibroblasts were harvested and analyzed for mCherry and GFP expression by
flow cytometry.
pp71 pools of immunodominant HCMV peptides, recognized
by both CD8+ and CD4+ T cells for PBMC stimulation
(Sylwester et al., 2005; Jackson et al., 2017b).
Healthy seropositive donor PBMC was thus stimulated with
these HCMV peptide pools for 48 h and the supernatant
harvested and added to the VDA at 24 hpi. Here supernatants
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FIGURE 3 | Analysis of the antiviral activity of PBMC stimulated with HCMV-infected fibroblast lysates and pools of HCMV synthetic peptides specific for pp65,
UL144,Gb, IE1,IE2, pp71, and US3. (A) Antiviral activity of supernatants derived from PBMC from three different donors stimulated with HCMV infected or uninfected
fibroblast lysates. PBMC were also stimulated with anti-CD3/CD28 antibodies to generate a positive control antiviral supernatant. Fibroblasts were infected at 0.01
MOI and co-cultured with 1:4 dilution of supernatant, following 9–11 days of incubation fibroblasts were harvested and analyzed for mCherry and GFP expression by
flow cytometry. Significance determined was by one-tailed T-test, p < 0.05. (B) Antiviral activity of HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71
and US3, and gB, as well as a polyclonal anti-CD3/CD28 antibody T cell stimulation as a positive control on five independent HCMV seropositive donors. Significance
determined by one-tailed T-test. Key: *p < 0.05; **p < 0.005; ***p < 0.0005.
from unstimulated PBMC were used as a negative control and
polyclonal stimulation was used as a positive control for antiviral
activity. The results show that two of the four donors tested
produced HCMV-specific antiviral supernatants in response
to stimulation with one or more of the peptide pools, while
two other donors (CMV319 and CMV332) did not produce
an antiviral response following peptide stimulation of PBMC
(Figure 3B). Hypothetically, the supernatants harvested from
donors CMV319 and CMV332 may not have been antiviral
in a VDA because these donors did not have memory T
cells to any of the HCMV peptides used to stimulate the T
cells. To investigate this, we quantified the HCMV peptide
specific IFNγ CD3+ T cell responses FluoroSpot of PBMC
from CMV319 and CMV332, alongside CMV1801. The results
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show that CMV1801 had positive FluoroSpot responses to pools
containing peptides covering pp71/US3 (Figure 4A), CMV332
had positive FluoroSpot responses to pools containing peptides
covering pp65/UL144 and IE1&2 (Figure 4B) and CMV319 had
positive IFNγ FluoroSpot responses to peptides from IE2 and
pp65 (data not shown).
This approach revealed a disconnect between the detection of
HCMV specific IFNγ responses (by FluoroSpot) and the ability
of these supernatants to exert antiviral activity. Both CMV1801
and CMV332 had positive IFNγ CD3+ T cell responses to
multiple HCMV peptide pools and in some cases at higher
frequency (e.g., pp65/UL144 and IE1/2), yet the supernatant from
CMV332 was not antiviral in the VDA (Figures 3B, 4A,B). We
therefore speculated that IFNγ was not the key cytokine that
determines antiviral activity in the supernatants. To address this,
HCMV peptide pools were used to stimulate PBMC from donor
CMV1801 for analysis in parallel. Specifically, one in an IFNγ
FluoroSpot plate (this would enumerate the T cell response and
deplete free IFNγ) and one in a non-antibody coated microtitre
plate so that IFNγ was present in the supernatant. Depletion of
IFNγ was verified by ELISA (Figure 4C) and also analyzed for
antiviral activity by VDA (Figure 4D).
The results show that despite CMV1801 having IFNγ-
producing T cells specific for pp65/UL144 and IE1&2 as well as
pp71/US3, only supernatants from pp71/US3-stimulated T cells
exhibited antiviral activity. Furthermore, this activity remained
following depletion of IFNγ from those supernatants. Taken
together, these data support our hypothesis that other factors,
beyond IFNγ, are important to the secreted antiviral immune
response to HCMV. Additionally, their identification may reveal
biomarkers of HCMV immunity.
PBMC and CD8+ T Cells Control HCMV in
an Autologous in vitro Co-culture Viral
Dissemination Assay
Thus, far our studies have focused on the anti-viral activity
of cytokines produced by stimulated T cells. However, direct
T cell-mediated cytotoxicity is an important mechanism of
control of viral infection. We previously developed an assay to
quantify CD8+ T cell and NK cell-mediated antiviral immunity,
measuring the lymphocyte-mediated inhibition of dissemination
of HCMV through a permissive autologous primary human
fibroblast monolayer (Jackson et al., 2014, 2019; Chen et al.,
2016). Similar assays used in other laboratories have utilized
partially HLA-matched fibroblasts and cytotoxic T lymphocytes
(Sinzger et al., 2007) or measured lysis of HCMV-infected
autologous fibroblasts with various NK cell clones derived from
independent donors (Carr et al., 2002). We therefore wanted to
assess the ability of whole PBMC, CD8+ T cells, and NK cells
from a cohort of seropositive and seronegative donors to control
HCMV in a fully autologous experimental system, and to assess
the relative contributions of these cell subsets (and their secreted
antiviral factors) to that control. This approach also allows us
to directly compare the antiviral efficacy of different cell subsets
from the same donor in the same experiment.
Primary autologous dermal fibroblasts were infected at a low
MOI (0.01), 24 h later these were co-cultured with either total
PBMC or purified CD8+ T cells or NK cells, across a range of
effector to target (E:T) cell ratios. After incubation for 10–14
days, fibroblasts were analyzed by flow cytometry for mCherry
and GFP expression. This comparison enabled us to determine
the HCMV specificity of this approach when purified CD8+ T
cells were used from both HCMV seropositive and seronegative
donors. The use of whole PBMC enables an assessment of
the antiviral capacity of innate immune cells (NK cells and
monocytes) as well as adaptive immune cells [CD8+ T cells and
gamma-delta (γδ) T cells].
The results are depicted using violin plots which show both
the frequency distribution of the VDA by population (e.g.,
seropositive donor PBMC control of virus spread), and the
individual data points for each donor. All data are normalized
such that the infected controls for each donor were set as
100% infection, and the uninfected controls were set at 0%
infection. At an E:T ratio of 2.5:1, HDFs co-cultured with
PBMC from seropositive donors inhibited virus infected cells
to between 0.6 and 15.4% of the normalized viral spread
(as evidenced by mCherry+ cells) of the infection control.
At the same E:T ratio, HDFs co-cultured with PBMC from
seronegative donors inhibited virus infected cells to between
34.9 and 100% of the normalized viral spread (mCherry+
cells) of the infection control. The data show PBMC from
HCMV seropositive donors (n = 8) were significantly better
at controlling viral spread (mCherry+ cells) than PBMC from
the HCMV seronegative cohort (n = 8) at E:T ratios of 5–
0.63:1. Similarly, the number of cells that progressed to late
stage infection (GFP+) was significantly decreased in the HCMV
seropositives vs. the HCMV seronegative cohort at E:T ratios of
2.5–0.63:1 (Figure 5).
We next analyzed the antiviral capacity and specificity of
purified CD8+ T cells from both HCMV seropositive and
seronegative individuals (Figure 6). The data show that CD8+
T cells from HCMV seropositive donors were significantly
more effective over a range of E:T ratios at inhibiting viral
spread (mCherry+) and infectious virus production (GFP+)
compared to CD8+ T cells from HCMV seronegative donors.
We also noted that at the higher E:T ratios CD8+ T cells
from HCMV seronegative donors were capable of exerting a
level of control, but this was lost rapidly, with only HCMV-
specific responses observed at E:T ratios of 2.5:1 and lower.
At an E:T ratio of 2.5:1, HDFs co-cultured with CD8+
T cells from seropositive donors inhibited virus infected
cells to between 0.5 and 54.1% of the normalized viral
spread (mCherry+ cells) of the infection control. At the
same E:T ratio, HDFs co-cultured with CD8+ T cells from
seronegative donors inhibited virus infected cells to between
70 and 125% of the viral spread (mCherry+ cells) of the
infection control.
Finally, we analyzed NK cells purified from PBMC. In contrast
to the results observed with PBMC and CD8+ T cells, the ability
of NK cells to control HCMV did not vary significantly by donor
serostatus (seropositive n = 8, seronegative n = 5) (Figure 7). It
was also notable that NK cell control of virus spread (mCherry+
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FIGURE 4 | Analysis of HCMV specific IFNγ FluoroSpot responses and antiviral activity of HCMV peptide stimulated supernatants with and without IFNγ depletion.
(A) IFNγ FluoroSpot responses to HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71 and US3, and gB, as well as a polyclonal anti-CD3/CD28
antibody T cell stimulation as a positive control of PBMC from donor CMV1801, calculated as spot-forming units (SFU) per 106 PBMC (background corrected). (B)
IFNγ FluoroSpot responses to HCMV peptide pools covering pp65 and UL144, IE1 and IE2, pp71 and US3, and gB, as well as a polyclonal anti-CD3/CD28 antibody
T cell stimulation as a positive control of PBMC from donor CMV332, calculated as spot-forming units (SFU) per 106 PBMC (background corrected). (C) The IFNγ
concentration of supernatants following peptide stimulation (black) or after IFNγ depletion by anti-IFNγ-coated FluoroSpot (cyan), measured by ELISA. (D) The effect of
IFNγ depletion on the antiviral activity of PBMC from donor CMV1801 stimulated with HCMV peptide pools for pp65/UL144, IE1&2, and pp71/US3 or anti-CD3/CD28
antibody. Bars labeled “IFNγ deplete” were harvested from anti-IFNγ antibody-coated FluoroSpot plates and added to a VDA in parallel with supernatants generated
with the same stimulants and PBMC cell number. Significance determined by one-tailed T-test. Key: *p < 0.05; **p < 0.005; ***p < 0.0005; ns, Not significant.
only cells) was poor compared to the control exerted by CD8+
T cells from HCMV seropositive donors over the same range of
E:T ratios. At an E:T ratio of 2.5:1, seropositive donors reduced
the normalized viral spread (mCherry+ cells) to 24.8–114.8%
compared to the infection control, while seronegative donors
reduced the normalized viral spread to 40.9–79.2% compared
to the infection control. It could also be seen from the violin
plots that some donors’ NK cells exerted better viral control than
others. In order to further illustrate this, we directly compared
the data from two HCMV seropositive donors in more detail
(Supplementary Figure 2). NK cells from donor AQU002 had
high level virus control (controlling virus spread and late gene
expression), while NK cells from AQU003 were unable to control
virus spread and had significantly less ability to control late virus
gene expression.
HCMV-Seropositive Solid Organ Transplant
Recipients (D+R+) Showed Comparable in
vitro Control of Viral Dissemination to
Healthy Controls
In our original analysis of HCMV-specific CD3+ T cell IFNγ
responses toHCMV lytic peptides, we show that the development
of these T cells was not predictive of resolution/recrudescence
of viraemia in a number (n = 7) of individuals in the D+R–
kidney transplant cohort (Figure 1). Approximately half of
D+R+ transplant recipients develop viraemia post-kidney or
liver transplant, but have shorter duration of viraemia than
D+R– patients suggesting pre-existing mature HCMV immune
responses are better able to control viraemia (Atabani et al.,
2012). In light of our analysis of cell-mediated immunity by
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FIGURE 5 | Antiviral activity of whole PBMC from HCMV seropositive and seronegative donors co-cultured with HCMV infected autologous fibroblasts. Violin plots
showing results from viral dissemination assays of PBMC co-cultured with HCMV infected fibroblasts for 10–14 days over a range of E:T ratios, fibroblasts were
harvested and analyzed for mCherry and GFP expression by flow cytometry. (A) Virus spread determined by mCherry+ fibroblasts and (B) by mCherry+ GFP+
fibroblasts. Cyan points show the range of control at each E:T for seropositive donors; magenta points are seronegative donors. Significance was determined by
one-tailed T-test. Key: *p < 0.05; **p < 0.005; ***p < 0.0005.
FIGURE 6 | Antiviral activity of purified CD8+ T cells from HCMV seropositive and seronegative donors co-cultured with HCMV infected autologous fibroblasts. Violin
plots showing results from Viral dissemination assays of PBMC co-cultured with HCMV infected fibroblasts for 10–14 days over a range of E:T ratios, fibroblasts were
harvested and analyzed for mCherry and GFP expression by flow cytometry. (A) Virus spread determined by mCherry+ fibroblasts and (B) by mCherry+ GFP+
fibroblasts. Cyan points show the range of control at each E:T for seropositive donors; magenta points are seronegative donors. Significance was determined by
one-tailed T-test. Key: *p < 0.05; **p < 0.005; ***p < 0.0005.
IFNγ Fluorospot and VDA in both HCMV seropositive and
seronegative healthy individuals, we tested the hypothesis that
seropositive transplant recipients who do not develop viraemia
have in vitro CMI more similar to healthy seropositives than
healthy seronegatives in our assays.
To investigate this, we identified four R+ patients who
received a D+ organ who were not on antiviral prophylaxis
and did not experience detectable viraemia post-transplantation.
In this R+ cohort, the HCMV-specific CD3+ T cell IFNγ
responses as well as total PBMC, CD8+ T cells and NK cells
by autologous VDA were analyzed. Total PBMC from each
R+ individual, collected ∼3 months (72–110 days) post-kidney
transplant, were stimulated with a panel of HCMV peptide pools
as before, and the responses enumerated by IFNγ FluoroSpot
(Supplementary Figure 3). The results show all the recipients
had a detectable T cell response to at least one of the peptide
pools. Recipient R02-00079 made IFNγ T cell responses to all the
pools tested, R02-00005 to all but one pool, and R02-00058 and
R02-00109 to a single pool each.
We next determined the anti-HCMV activity of the PBMC,
CD8+, and NK cells derived from the same R+ kidney transplant
recipients. The results demonstrate that PBMC derived from
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FIGURE 7 | Antiviral activity of purified NK cells from HCMV seropositive and seronegative donors co-cultured with HCMV infected autologous fibroblasts. Violin plots
showing results from Viral dissemination assays of PBMC co-cultured with HCMV infected fibroblasts for 10–14 days over a range of E:T ratios, fibroblasts were
harvested and analyzed for mCherry and GFP expression by flow cytometry. (A) Virus spread determined by mCherry+ fibroblasts and (B) by mCherry+ GFP+
fibroblasts. Cyan points show the range of control at each E:T for seropositive donors; magenta points are seronegative donors. Significance was determined by
one-tailed T-test. Key: *p < 0.05; **p < 0.005; ***p < 0.0005.
the seropositive kidney transplant recipients 3 months post-
transplant were just as effective at controlling HCMV as healthy
seropositive PBMC and clearly different from the response in
seronegatives (Figure 8A). At an E:T ratio of 1.25, D+R+ PBMC
from time point T3 (∼3 months post-transplant) controlled
the spread of HCMV with a range 0.7–24.5% of the infected
control (mCherry+ cells), compared to a range of 1.3–55.6%
in healthy seropositives and 33–92.7% in healthy seronegatives.
This was also recapitulated in CD8+ T cells analyses where
again R+ patient cells had a similar pattern of control to
CD8+ T cells derived from healthy seropositives (Figure 8B).
Correspondingly, NK cells from the R+ kidney transplant
recipients had a similar range of virus control to both HCMV
seropositive and seronegative healthy donors (Figure 8C).
DISCUSSION
Quantification of the magnitude of the immune response against
HCMV has long been investigated as a method for predicting
individuals better able to control viral replication in clinical
settings. In the context of CMI this has centered on measuring
the frequency of IFNy CD3+ T cells that recognize HCMV
antigens, with the assumption that a direct correlation between
frequency and control exists. In this study, we investigated
CMI to HCMV in both SOT recipients and healthy controls.
These in vitro CMI assays suggest that the use of IFNγ as a
proxy for HCMV-specific control in vivo may not represent
the best measure of the antiviral activity of immune cells from
immune suppressed SOT recipients. Our view that measurement
of IFNγ is not a robust biomarker is supported by two pieces
of evidence: firstly, a clear lack of correlation between CD3+ T
cell IFNγ responses and DNAemia resolution in a small cohort
of D+R– kidney transplant patients undergoing primary HCMV
infection was observed. Secondly, no correlation between IFNγ
production from HCMV peptide stimulated PBMC and the
ability of these supernatants to inhibit virus dissemination was
observed. Instead, we established that a fully autologous HCMV
infection and immune cell co-culture system, incorporating both
direct cell-cell and secreted antiviral immunity, was much more
effective in distinguishing between HCMV-specific immunity
in healthy seropositive and seronegative donors. Using this
approach, we demonstrated potent antiviral activity of CD8+
T cells and correlated this with control of viraemia in D+R+
transplant recipients.
An important aspect of our study was the increased choice
of antigens used to stimulate PBMC. This allowed us to test
whether the variable predictive power of IFNγ-focused CMI
assays was due to the limited choice of HCMV antigens used for
stimulation of T cells. Many commercial assays which enumerate
IFNγ responses to HCMV (e.g., T.Track CMV and T.SPOT-
CMV) focus on a narrow range of lytic antigens, such as IE1
and pp65. However a number of studies have now demonstrated
that the CD4+ and CD8+ T cell responses to HCMV are
broader than this, and that not all seropositive donors will
respond to IE1/pp65 (Sylwester et al., 2005; Jackson et al., 2014,
2017a). Some studies have suggested that serology alone may
over-estimate the proportion of healthy individuals who are
HCMV seropositive compared to testing for HCMV serostatus
by Western blot (Sukdolak et al., 2013). We do not believe that
false-positive HCMV serology explains all cases of individuals
who fail to make a detectable IFNγ response to pp65, as we
and others have noted that serostatus cannot be accurately
predicted by the CD4+ or CD8+ T cell response to a single
ORF, but rather by the combination of detectable responses
to several ORFs (Sylwester et al., 2005; Jackson et al., 2017b).
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FIGURE 8 | Antiviral activity of PBMC, CD8+ T cells, and NK cells from HCMV seropositive and seronegative donors and from non-viraemic D+R+ kidney transplant
recipients co-cultured with HCMV infected autologous fibroblasts. Violin plots showing results from Viral dissemination assays of (A) PBMC, (B) CD8+ T cells, and (C)
NK cells. Cells were co-cultured with HCMV infected fibroblasts for 10–14 days over a range of E:T ratios, fibroblasts were harvested and analyzed for mCherry and
GFP expression by flow cytometry. Virus spread determined by mCherry+ fibroblasts and by mCherry+ GFP+ fibroblasts. D+R+ kidney transplant recipients were
tested in a VDA from samples collected immediately pre-transplant (T1), at 1–2 months (T2), and 2 months post-transplant. At T3 (post-transplant), PBMC, CD8+ T
cells, and NK cells were not statistically significantly different from healthy seropositives in their control of virus dissemination. Cyan points show the range of control at
each E:T for seropositive donors; magenta points are seronegative donors. Purple points are samples taken immediately pre-transplant. Blue points are samples
taken 1–2 months post-transplant. Gray points are samples taken 3 months post-transplant. Significance was determined by one-tailed T-test. Key:
*p < 0.05; **p < 0.005; ***p < 0.0005.
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By increasing the range of immunodominant peptides used
for CD3+ T cell stimulation beyond that used in commercial
assays, we could better enumerate IFNγ FluoroSpot responses
in seven D+R– SOT recipients. Importantly, this approach
still did not identify any obvious differences in the immune
responses of these patients to provide an explanation for why
some recipients had resolution of viraemia, and others recurrent
viraemia despite a broad T cell response. We considered delayed
immune reconstitution and immune suppression as factors in the
occurrence and recurrence of viraemia, as HCMV-specific CMI
is known to reconstitute more quickly in R+ than R– transplant
recipients (Eid et al., 2010) and to reconstitute at different rates
in different patients (Abate et al., 2010). However, that does
not seem to explain the differences between patients who did
and did not control viraemia, as all patients mounted T cell
responses similar in magnitude and breadth to those seen in
healthy seropositive donors. Additionally, all patients received
similar immunosuppressive regimes, suggesting other factors
might explain the variable efficacy of their T cells.
A major aim of this study was to develop a robust method to
identify and assess antiviral CMI responses in vitro to empower
our ongoing work aimed at understanding the key aspects of
the immune response that provide protection in some, but not
all, transplant patients. It is well-established that HCMV-infected
cell lysates or peptide stimulation can be used to generate IFNγ
responses from PBMC and CD4/8+ T cells (e.g., Sinclair et al.,
2004; Jackson et al., 2017b; Chanouzas et al., 2018). However,
it became clear that this form of stimulation did not always
translate directly into effective control of viral replication in our
assays. Furthermore, they again confirmed that antiviral activity
did not correlate with ability of T cells to produce IFNγ. An
obvious interpretation is that other cytokines play an important
role in the control of viral replication. It is interesting to note
that anti-HCMV activity of monocyte derived macrophages has
been observed and that this was not mediated by IFNγ nor
primary IFNα or IFNβ although the identity of the secreted factor
responsible for the activity was not determined (Becker et al.,
2018). Other studies have shown that even in the presence of
IFNγ or IFNα or IFNβ neutralizing antibodies, HCMV infection
can still be controlled by lymphocytes in a non-cytotoxic manner,
with granzymes implicated in control (Shan et al., 2020). A non-
biased mass spectrometry-based approach is likely to be required
to elucidate the key antiviral components of effective secretomes.
Taken together we feel that an antiviral assay system based on
stimulation of PBMC with HCMV antigens did not provide
sufficient specificity and sensitivity as a viable technique to better
measure effective CMI in the transplant setting.
To address this, we developed a fully autologous co-culture
system to determine anti-HCMV activity of PBMC and/or
isolated lymphocyte subsets. Without the need to use individual
cytokines as proxies for potential in vivo control we reasoned it
could provide a much more direct measure of anti-HCMV status
of a transplant patient’s immune response. One important aspect
of our approach is that these responses can be characterized
in aggregate (PBMC) and studied at the individual lymphocyte
population level (NK or CD8+ T cells). As such the approach
could potentially inform us about the relative importance of
individual lymphocyte subsets and the interplay between these
(as seen when PBMC is utilized) in order to mediate effective
antiviral responses. Whole PBMC include innate, adaptive and
so-called “innately adaptive” immune cells (Ferreira, 2013),
which have both individual and potentially synergistic antiviral
activity. The antiviral capabilities of PBMC would include
directly cytotoxic effector function, and secretion of antiviral
soluble factors. In addition, the use of a dual-color fluorescent
HCMV strain allows the differential quantification of whether
control acts on virus spread or late viral gene expression, or both.
As such, the inhibition of viral dissemination demonstrated by
PBMC from healthy seronegatives at higher E:T ratios was to
be expected, as innate immune cells are present. However, the
antiviral activity is rapidly diluted, and this is consistent with
a degree of innate cell-mediated (NK cell) control of HCMV
spread in both HCMV seropositives and seronegatives that we
tested. It was however interesting to observe that NK cells derived
from HCMV seropositive donors were no better or worse at
controlling HCMV and that individuals with NK cells with good
or poor antiviral control could be observed in both groups. We
have previously shown that HCMV-specific memory T cells are
not present in HCMV seronegative PBMC (Sylwester et al., 2005;
Jackson et al., 2017b), which also explains why antiviral activity of
PBMC from seronegative donors dilutes rapidly. Consequently,
it is not surprising that very clear differences in the antiviral
activity of CD8+ T cells can be seen between HCMV seropositive
and seronegative donors reflecting the fundamental difference in
efficacy of primary and memory T cell responses.
Another major advantage of determining antiviral capacity
in this viral dissemination co-culture system, is the use of a
low passage strain of HCMV that expresses the full complement
of immune evasion genes. As such viral derived antigens,
both incoming from initial virus infection and produced de
novo, are processed and presented in the correct temporal and
immune evasion contexts. This being the case, it is clear that
CD8+ T cells derived from seropositive donors are still able
to exert antiviral effector function despite immunoevasins (e.g.,
US2,3,6,11) that interfere with MHC Class I processing and
cell surface expression (Reddehase, 2002; Wills et al., 2015).
Indeed, this is consistent with HCMV being asymptomatic in
healthy individuals due to effective immune control. What this
may reflect is that incoming HCMV proteins are processed and
presented for T cell recognition prior to the virus interfering
with this process, as has been suggested for Epstein-Barr virus
(Forrest et al., 2018). It should also be noted that the ability of
some HCMV immunoevasins to prevent MHC class I processing
and presentation is dependent on the genotype of the host [e.g.,
US2 cannot bind HLA-B∗07 and ∗27 as efficiently as HLA-A
genotypes (Gewurz et al., 2001; Reddehase, 2002); US11 degrades
HLA-A but is less effective against HLA-B, with HLA-B∗44:02
particularly resistant (Zimmermann et al., 2019)]. Thus, the HLA
genotype of the donor will contribute to the effectiveness of
HCMV evasion of CD8+ T cell control.
The nature of the responding HCMV specific T cells is
also an important factor. It is recognized that CD8+ T cells
with a high avidity for HCMV peptides would require far less
stimulation with their cognate antigens than low avidity CD8+
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T cells (Villacres et al., 2003), and have potent cytotoxicity,
IFNγ production and proliferation in response to HCMV antigen
stimulation (Villacres et al., 2003; Ogonek et al., 2017). It has
been shown that only a relatively small amount of cell surface
MHC class I expression is required to trigger a cytotoxic T cell
response to e.g., IE1 further supporting the hypothesis that even
minimal MHC class I presentation (despite viral MHC class I
immunoevasins) of HCMV antigens to seropositive donor CD8+
T cells is sufficient for a strong antiviral response to infected
fibroblasts (Besold et al., 2009). High affinity identical or near-
identical public TCR sequences arise convergently in unrelated
individuals in response to HCMV infection, via antigen-driven
selection (Gras et al., 2009). These high-affinity TCRs are
part of an evolving T cell response to HCMV antigens in
seropositive donors during long term carriage and reactivation
events (Schober et al., 2018). More broadly, these observations
are again consistent with the concept that measurement of the
quality of an immune response is more important than quantity.
During the process of establishing this assay, our studies
suggest that there is considerable variability in the ability of
different donors’ NK cells to control HCMV spread and late
gene expression. Furthermore, the data also suggest that no
statistically significant difference in the ability of NK cells
isolated from seropositives and seronegatives to control HCMV
dissemination is evident. This observation is supported by a
previous publication studying an independent cohort of NK cell
donors, using non-autologous indicator fibroblasts (Chen et al.,
2016), and work by other groups showing that not all NK cell
clones are equally effective at lysing HCMV-infected autologous
fibroblasts (Carr et al., 2002). The ability of NK cells to inhibit
late viral gene expression, compared to inhibition of virus spread,
is also similar to results from Wu et al. (2015) who observed
reduced HCMV UL86 (major capsid protein) expression in NK-
fibroblast co-cultures, even though IE antigen expression was
seen in almost every cell.
In this study, we did not explore the phenotypic characteristics
of the NK cells present in each donor, but it has been
shown that there are a number of different NK cell subsets
within an individual, independently expressing activating and
inhibitory receptors (Cooper et al., 2001). HCMV may further
epigenetically reprogram and diversify NK cell function and
receptor expression in some subsets (Lee et al., 2015; Schlums
et al., 2015). LIR1+ and LIR1− NK cells have also been
shown to have differential activity against HCMV strains in a
viral dissemination assay, suggesting interactions with specific
residues within UL18 (Chen et al., 2016). The differences in
NK cell control between donors may also reflect a number of
host factors (Patel et al., 2018), including NKG2C copy number
(Muntasell et al., 2013), HLA/KIR genotype interactions (Hadaya
et al., 2008), other host genetic factors (Yu et al., 2018), age
(Manser and Uhrberg, 2016), and underlying health conditions
(Brunetta et al., 2010). For seropositives, it may also be influenced
by the HCMV strain to which the donor has previously been
exposed (Chen et al., 2016) and how long ago the donor was
infected (Vieira Braga et al., 2015). HCMV also has a repertoire
of immunoevasins which impair or reduce NK cell activation
(De Pelsmaeker et al., 2018). It is likely that the balance between
evasion of NK cell control by the virus and superior NK cell
recognition by some donors due to host factors leads to the
complex variation in control of virus spread and late gene
expression seen in our healthy donor cohorts. Importantly, our
assay system provides the framework to systematically investigate
these different variables in future studies.
In this study, we have defined a functional assay that measures
HCMV cell-mediated immunity and established the baseline
antiviral CMI of healthy HCMV seropositives and seronegatives.
This assay is highly tractable and will allow the systematic
investigation of host and viral factors that influence the ability of
clinically relevant patient populations to control (or not control)
HCMV viraemia. Importantly, this assay relies on a measure of
antiviral activity, not T cell activation. The implications of this are
obvious: for example, individuals infected with multiple HCMV
strains (e.g., D+R+ cohort) may control their own virus but not
the infection with a new strain as effectively. Given that it is likely
that the R+ individuals’ T cells would likely recognize conserved
HCMV antigens from either strain we can now ask how this
translates into the control of the replication of multiple strains
of HCMV by combining this assay with the power of whole
viral genome sequencing and HCMV BAC recombineering. It is
anticipated that the integration of these approaches will shed new
light on the immune parameters and mechanisms critical for the
control of HCMV in vivo.
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